Boehringer Ingelheim Pharmaceuticals Plans Richmond Lab

Published November 2001

RICHMOND, VA. -

Boehringer Ingelheim Pharmaceuticals is planning a new 16-researcher R&D lab for pharmaceutical synthesis in Richmond's Virginia Biotechnology Research Park. Over the next five years, Boehringer plans to invest $2.5 million in the facility. Based in Germany, Boehringer's U.S. headquarters are in Connecticut. Copyright 2008 Tradeline Inc.
All Rights Reserved
ISSN: 1096-4894